It was the first 15 shares mi amigo. I don't know if I can swing a 100,000 at these high prices. I keep waiting for the price to drop. Actually, looking back at it, those of us who were in it at the beginning keep expecting a spectacular rise in price after that first shot. It might still happen, but the stock has settled (although grossly undervalued) into being an ordinary biopharm startup with no pizzazz and no differentiation from other similar stock and as such is trading like an ordinary stock in this slot. To get out of it, the company needs to start raking in big, big money, or merge, partnership up, or sell itself. JMHO.
News 
Market Data 
Discover 
